Next-gen CRISPR for cell therapy
Co-founded by Jennifer Doudna, Caribou Biosciences uses its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology to develop allogeneic cell therapies for cancer. Their platform enables off-the-shelf CAR-T cells.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| CB-010 | B-cell Non-Hodgkin Lymphoma | Phase 1 | chRDNA CRISPR |
| CB-011 | Multiple Myeloma | Phase 1 | chRDNA CRISPR |
| CB-012 | AML | Phase 1 | chRDNA CRISPR |
Life Biosciences launched the first-ever human trial of epigenetic reprogramming in January 2026 — an AAV gene therapy that uses three Yamanaka factors to reverse aging in the eye. Here's the full story of the company, its science, and what it means for the future of longevity medicine.
From billion-dollar reprogramming ventures to canine longevity drugs, here are the biotech companies leading the charge against aging in 2026.